UNCY - Unicycive: This Biotech Company Receives Promising Results From New Trial
(NewsDirect)
By Johnny Rice, Benzinga
UnicyciveTherapeutics Inc. (NASDAQ: UNCY) is a biotechnology companydeveloping drug candidates currently focused on kidney disease. Theinnovative treatments may have vast potential outside of the specificsof kidney disease as well.
Currently, the company has two treatments indevelopment: Renazorb, for treatment of hyperphosphatemia in patientswith chronic kidney disease, and UNI-494, for treatment of acutekidney injury.
Thelatter recently passed through a new round of preclinical trials. Theresults were described as “very encouraging” by a leading expertin the field of AKI (acute kidney injury) research.
Learn more here: MightyMitochondria: This Company is Developing A Novel Drug for KidneyDisease By Targeting The Powerhouse Of Human Cells
Watch the videohere:
Thisarticle was originally published on Benzinga here .
UnicyciveTherapeutics is a biotechnology company developing novel treatmentsfor kidney diseases. Unicycive’s lead drug, Renazorb, is a novelphosphate binding agent being developed for the treatment ofhyperphosphatemia. UNI-494 is a patent-protected new chemical entityin late preclinical development for the treatment of acute kidneyinjury.
This post contains sponsored advertising content.This content is for informational purposes only and is not intended tobe investing advice.
Contact Details
AnneMarie Fields - Stern Investor Relations
+1 212-362-1200
CompanyWebsite
Copyright (c) 2023 TheNewswire - All rights reserved.